Summary
Eighty-four previously treated adult patients with acute leukemia and malignant lymphoma were treated with (2″R)-4′-O-tetrahydropyranyladriamycin (THP). THP (10–55 mg/m2) was administered by i.v. bolus injection daily for acute leukemia, and according to three different schedules for malignant lymphoma: daily, weekly or once every 3–4 weeks. Complete and partial remission (CR and PR) were achieved by 1 (5%) and 3 of 19 patients with acute myelogenous leukemia and by 2 (13%) and 3 of 15 patients with acute lymphoblastic leukemia, respectively. All CRs were in the groups receiving 25 mg/m2 THP daily. CR and PR were achieved by 6 (14%) and 8 of 42 patients with non-Hodgkin lymphoma (NHL) and by 4 (50%) and 2 of 8 patients with Hodgkin's disease (HD), respectively. No particular sensitivity was found among the subtypes of NHL and HD. Response (CR+PR) was noted in 10 (40%) of 25 patients treated every 3–4 weeks, in 1 (17%) of 6 treated weekly, and in 9 (47%) of 19 treated daily. The major side effects were myelosuppression and gastrointestinal toxicities. Alopecia was observed in only 10 (12%) patients. ECG abnormalities were observed in 7 (10%) patients, all of whom had previously been treated with other anthracyclines. No severe cardiotoxicity was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blum RH (1975) An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemothr Rep 6: 247–251
Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 149–259
Boiron M, Jacquillat C, Weil M, Tanzer J, Levy D, Sultan C, Bernard J (1969) Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet I: 330–333
Bonadonna G, Monfardini S, Lena MD, Fossa-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin (NCS-123127) Cancer Res 30: 2572–2582
Bornstein RS, Theologides A, Kennedy BJ (1969) Daunorubicin in acute myelogenous leukemia in adults. J Am Med Assoc 207: 1301–1306
Carter SK (1975) Adriamycin — a review. J Natl Cancer Inst 55: 1265–1274
Carter SK (1980) The clinical evaluation of analogs: III. Anthracyclines. Cancer Chemother Pharmacol 4: 5–10
Coltman CA (1975) Adriamycin (NCS-123127) in the treatment of lymphomas: Southwest Oncology Group Studies. Cancer Chemother Rep 6: 375–380
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G (1979) Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP) as observed by electron and light microscopy. J Antibiot (Tokyo) 32: 1085–1086
Jones B, Holland JK, Morrison AR, Lee SL, Sinks LF, Cuttner J, Rausen A, Kung F, Pluss HJ, Haurani FI, Patterson RB, Blom J, Burgert EM Jr, Moon JH, Chevalier L, Sawitsky A, Albala MM, Forcier RJ, Falkson GF, Glidewell O (1971) Daunorubicin (NSC 82151) in the treatment of advanced childhood lymphoblastic leukemia. Cancer Res 31: 84–90
Kimura K (1986) A phase II study of (2″R)-4′-o-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. Gan-to-Kagakuryoho 13: 368–375
Kitajima K, Takashashi I, Yorimitsu S, Koi B, Tokioka M, Lai M, Masaki K, Sakano M, Hara M, Adachi T, Kawakubo K, Kimura I, Sanada H (1980) Treatment of refractory adult leukemia with aclacinomycin-A — phase II study. Gan-to-Kagakuryoho 7: 1220–1227
Kunitomo S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′-o-tetrahydropyranyladriamycin. J Antibiot (Tokyo) 36: 312–317
Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, Umezawa H (1984) Cellular uptake and effulux and cytostatic activity of 4′-o-tetrahydropyranyladriamycin in adriamycin-sensitive and-resistant tumor cell lines. J Antibiot (Tokyo) 37: 1697–1702
Majima H (1983) Exploratory clinical study of 4′-o-tetrahydropyranyl doxorubicin (THP) — phase I. Gan-to-Kagakuryoho 10: 134–140
Majima H, Iguchi H, Tone H (1986) Pharmacokinetic studies of THP (tetrahydropyranyladriamycin). Gan-to-Kagakuryoho 13: 542–548
Malpas JS, Scott RB (1968) Rubidomycin in acute leukaemia in adults. Br Med J III: 227–229
Mathé G, Bayssas M, Guouvenia J, Dantchev D, Ribaud P, Machover D, Misset JL, Schwarzenberg L, Jasmin C, Hayat M (1978) Preliminary results of a phase II trial of aclacinomycin in acute leukemia and lymphosarcoma. Cancer Chemother Pharmacol 1: 259–262
Miller AB, Hoogdtraten B, Staquet M, Winkle A (1981) Reporting results of cancer treatment. Cancer 47: 207–215
Nakajima O, Imamura Y, Matsumoto A, Koyama Y, Shomura T, Kawamura K, Murata S (1986) Comparative studies on pharmacokinetics between THP and adriamycin in the same patients. Gan-to-Gagakuryoho 13: 261–270
Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda N, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline, 4′-o-tetrahydro-pyranyladriamycin. Invest New Drugs 1: 169–172
Saito T, Kasai Y, Wakui A, Furue H, Majima H, Niitani H, Niijima T, Takeda C, Abe O, Kimura K, Ohta K, Yamada K, Taguchi T, Kimura J, Hattori T, Inokuchi K, Kato T (1986) Phase II study of (2″R)-4′-o-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Gan-to-Kagakuryoho 13: 1060–1069
Suzuki H, Kawashima K, Yamada K, Minami S, Kato Y, Tanimoto M, Yamada H, Isobe K, Hayashi K, Yamaguchi H, Takamatsu J, Watanabe E, Kodera Y, Shiku H, Kamiya T, Ohno R, Morishita H, Yokomaku S, Yoshida K, Ogura M (1980) Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia. Jpn J Clin Oncol 10: 111–118
Takubo T, Sonoda T, Namiuchi S, Ueda T, Shibata H, Nakamura H, Masaoka T, Yoshitake J (1980) Clinical results of aclacinomycin A in hematopoietic malignancies. Gan-to-Kagakuryoho 7: 1361–1365
Tan C, Tasaka H, Yu K-P, Murphy ML, Karnofsky DA (1967) Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20: 333–353
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′-o-Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42: 1462–1467
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyrany derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32: 1082–1084
Uzuka Y, Saito Y (1985) THP in the treatment of acute promyelocytic leukemia. Tohoku J Exp Med 146: 1–8
Wakui A, Yokoyama M, Konno K, Nakai Y, Sakano T, Koyama Y, Imamura Y, Nakajima O, Niijima T, Akaza H, Kimura I, Ohnoshi T, Hiraki S, Kato T, Nishimura H, Umezu J, Saito T (1985) Phase I trial of 4′-o-tetrahydropyranyldoxorubicin (THP) — multi-institutional cooperative study. Gan-to-Kagakuryoho 12: 118–124
Wiernik PH (1975) Use of adriamycin (NSC 123127) in hematologic malignancies. Cancer Chemother Rep 6: 369–373
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Ohno, R., Kimura, K., Amaki, I. et al. Treatment of acute leukemia and malignant lymphoma with (2″R)-4′-O-tetrahydropyranyladriamycin. Cancer Chemother. Pharmacol. 20, 230–234 (1987). https://doi.org/10.1007/BF00570491
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570491